Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price objective (down previously from $28.00) on shares of Bio-Path in a report on Monday.
Shares of Bio-Path stock opened at $7.30 on Tuesday. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The firm has a market cap of $21.02 million, a price-to-earnings ratio of -0.51 and a beta of 3.05. The company has a 50-day moving average of $10.22 and a 200 day moving average of $12.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.85 and a quick ratio of 13.85.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Story: Candlestick
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.